Search company, investor...

Chemogen

chemogen.com

Founded Year

2000

Stage

Unattributed VC | Alive

Total Raised

$250K

Last Raised

$250K | 22 yrs ago

About Chemogen

Chemogen develops rapid diagnostic tests for infectious diseases, currently focused on TB

Headquarters Location

125 John Roberts Road Suite 5

South Portland, Maine, 04106,

United States

207-772-2931

Missing: Chemogen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Chemogen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Chemogen Patents

Chemogen has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/19/2009

11/15/2011

Nontuberculous mycobacteria, Acid fast bacilli, Tuberculosis, Medical tests, HIV/AIDS

Grant

Application Date

10/19/2009

Grant Date

11/15/2011

Title

Related Topics

Nontuberculous mycobacteria, Acid fast bacilli, Tuberculosis, Medical tests, HIV/AIDS

Status

Grant

Chemogen Frequently Asked Questions (FAQ)

  • When was Chemogen founded?

    Chemogen was founded in 2000.

  • Where is Chemogen's headquarters?

    Chemogen's headquarters is located at 125 John Roberts Road, South Portland.

  • What is Chemogen's latest funding round?

    Chemogen's latest funding round is Unattributed VC.

  • How much did Chemogen raise?

    Chemogen raised a total of $250K.

  • Who are the investors of Chemogen?

    Investors of Chemogen include CEI Ventures.

  • Who are Chemogen's competitors?

    Competitors of Chemogen include Veredus Laboratories, Epocal, Minomic International, Advanced Cell Diagnostics, Molecular Detection and 12 more.

Compare Chemogen to Competitors

V
ViralTest

ViralTest offers molecular-based diagnostics development for niche infectious diseases markets.

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

H
Hx Diagnostics

Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.

L
LifeLineLab S.r.l.

Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.

M
Modules for Novel Diagnostics

MND Diagnostics is a healthcare company focused on disease diagnosis. The medical device company has developed a diagnostic detection platform which aims to be rapid, low-priced and portable.

K
Kjaya

Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.